In conclusion, this case describes the significant clinical, diagnostic and therapeutic differences between STAT5B-RARα t(17;17) and PML-RARα t(15;17) fusion-positive APL and highlights the role of molecular diagnostics, cytogenetics and flow cytometry in the identification of this rare APL variant. This evidence concerns the gene PML and acute promyelocytic leukemia.